Browsing Tag
HIV
16 posts
Phase 3 analysis positions pritelivir as novel oral option for severe HSV in HIV
Phase 3 data position pritelivir as a novel oral option for severe HSV in HIV. Discover what this means for AiCuris and the antiviral market.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
Merck’s once-daily DOR/ISL HIV therapy delivers sustained viral control and weight stability in Phase 3 results
Discover how Merck’s DOR/ISL HIV therapy preserves viral suppression and metabolic stability, signaling a new era in patient-centered HIV care.
Comprehensive guide to HIV: Transmission, symptoms, diagnosis, and treatment
Human Immunodeficiency Virus (HIV) continues to pose significant challenges worldwide, not only as a public health issue but…
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead…
Strides Pharma subsidiary gains FDA approval for EET tablets
Strides Pharma Science Limited has announced a significant achievement, with its wholly-owned subsidiary, Strides Pharma Global Pte. Limited…
EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC)…
Strides Pharma’s HIV generic drug gets tentative FDA approval
Strides Pharma Science Limited (Strides) announced that its Singapore-based stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited,…
Aurobindo Pharma gets tentative FDA approval for generic HIV treatment for children
Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)’s tentative…
Gilead Sciences lenacapavir shows potential in transforming HIV clinical care
New data presented by Gilead Sciences, Inc. has highlighted the efficacy, safety, and patient tolerability of Sunlenca (lenacapavir),…